Tekla Capital Management LLC Fibrogen Inc Transaction History

Tekla Capital Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$31.0 - $55.72 $6.02 Million - $10.8 Million	-194,270 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$34.58 - $48.06 $1.34 Million - $1.87 Million	-38,872 Reduced 16.67%	194,270 $8.33 Million
Q3 2019 Nov 13, 2019	SELL	$36.98 - $48.45 $413,362 - $541,574	-11,178 Reduced 4.58%	233,142 $8.62 Million
Q2 2019 Aug 14, 2019	BUY	$35.13 - $55.53 $2.41 Million - $3.81 Million	68,578 Added 39.02%	244,320 $11 Million
Q1 2019 May 14, 2019	SELL	$42.83 - $59.91 $1.59 Million - $2.22 Million	-37,021 Reduced 17.4%	175,742 $9.55 Million
Q4 2018 Feb 13, 2019	BUY	$37.97 - $60.16 $1.31 Million - $2.08 Million	34,556 Added 19.39%	212,763 $9.85 Million
Q2 2018 Aug 13, 2018	BUY	$44.9 - $64.95 $3.32 Million - $4.8 Million	73,900 Added 70.85%	178,207 $11.2 Million
Q1 2018 May 14, 2018	BUY	$45.35 - $61.65 $4.73 Million - $6.43 Million	104,307 New	104,307 $4.82 Million

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Tekla Capital Management LLC with notifications on news.